Motexafin gadolinium
Encyclopedia
Motexafin gadolinium is an inhibitor of thioredoxin reductase
and ribonucleotide reductase
. It has been proposed as a possible chemotherapeutic agent
in the treatment of brain cancer.
Food and Drug Administration
(FDA) by Pharmacyclics, Inc.
On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.
Thioredoxin reductase
Thioredoxin Reductases are the only known enzymes to reduce thioredoxin . Two classes of thioredoxin reductase have been identified: one class in bacteria and some eukaryotes and one in animals. Both classes are flavoproteins which function as homodimers...
and ribonucleotide reductase
Ribonucleotide reductase
Ribonucleotide reductase is an enzyme that catalyzes the formation of deoxyribonucleotides from ribonucleotides. Deoxyribonucleotides in turn are used in the synthesis of DNA. The reaction catalyzed by RNR is strictly conserved in all living organisms...
. It has been proposed as a possible chemotherapeutic agent
Chemotherapy
Chemotherapy is the treatment of cancer with an antineoplastic drug or with a combination of such drugs into a standardized treatment regimen....
in the treatment of brain cancer.
History
On May 9, 2006, a New Drug Application was submitted to the United StatesUnited States
The United States of America is a federal constitutional republic comprising fifty states and a federal district...
Food and Drug Administration
Food and Drug Administration
The Food and Drug Administration is an agency of the United States Department of Health and Human Services, one of the United States federal executive departments...
(FDA) by Pharmacyclics, Inc.
On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.